Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808151) titled 'Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Solstice Oncology, Inc.
Condition:
Colon Cancer
Microsatellite Stable (MSS) Colon Cancer
Proficient Mismatch Repair (pMMR) Colon Cancer
Intervention:
Drug: Pembrolizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2026
Target Sample Size: 100
Countries of Recruitment:
United States
Belgium
I...